Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life

Abstract

The epidemiology of psoriasis has not been widely assessed in Polish population so far. This study aimed to investigate psoriasis epidemiological situation by evaluating disease course and severity, management, comorbidities, environmental factors, and knowledge about this disorder among psoriatic patients in Poland. A cross-sectional cohort population-based study enrolled 1080 psoriatic patients and 1200 controls. The mean age of psoriasis onset was 27.6 years; 78.24% had type I psoriasis. Positive family history of psoriasis was reported in 44.81% of patients, whereas itch was reported in vast majority of patients (83.33%). Based on PASI score moderate psoriasis was the most common in studied group (mean 12.63 ± 9.33, range 0–67.2). The DLQI score (12.01 ± 7.41, range 0–30.0) indicated a very large effect of psoriasis on the quality of life. Hypertension was the most prevalent comorbidity (33.80%), followed by obesity (16.85%) and dyslipidemia (11.85%). Stress was the foremost cause of disease exacerbation (66.20%); however, infections (44.07%) and seasonal changes (45.09%) had also an impact on the course of psoriasis. Psoriatic patients were more often smokers (37.59%) vs. general population (27.50%; p < 0.0001). In conclusion, epidemiological studies help clinicians in better disease and patient understanding, which may translate into better management and patient compliance.

Clinical Feature, Lifestyle Behavior and Non-Communicable Diseases Comorbidities Among Psoriasis Patients in Shanghai: Gender Disparity Analysis Based on a Cross-Sectional Study

“…This study obtained outcomes consistent with already available data. 14,15 In this study, gender disparity analysis indicated that male patients had higher prevalence of tobacco smoking, alcohol drinking and tea drinking, had younger age of smoking and alcohol drinking initiation, with longer duration of tobacco smoking and alcohol drinking than female patients. Moreover, male patients had elder age of disease initiation and longer disease duration than female patients, and the prevalence of diabetes, hypertension, hyperlipidemia, and metabolic syndrome in male patients were higher than female patients.…”

Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004–2022

“…The turn of the millennium ushered in a new therapeutic era as monoclonal antibodies and fusion proteins, also known as biologics, revolutionized the antipsoriatic treatment of patients with moderate to severe plaque psoriasis. Those patients have a high need for medical care 1–3 . In fact, psoriasis was reported to be the third most frequently treated disease in German dermatology clinics 4 .…”

“…Those patients have a high need for medical care. [1][2][3] In fact, psoriasis was reported to be the third most frequently treated disease in German dermatology clinics. 4 With the introduction of the interleukin (IL)-17 and IL-23p19 inhibitors for the treatment of plaque psoriasis, the efficacy has reached new heights, with more patients than ever achieving an excellent treatment response (i.e., ≥ 90% clearance of psoriatic lesions [Psoriasis Area and Severity Index, PASI 90 response], and full remission [PASI 100 response]) in clinical trials.…”

Preisträger stellen sich vor: Thomas Graier erhält den Versorgungsforschungspreis der ÖGDV 2022

“…Psoriasis ist eine häufig vorkommende, chronische, immun-mediierte Erkrankung der Haut, welche aufgrund ihrer moderaten bis schweren Ausprägung bei vielen Patient:innen einer systemischen Therapie bedarf. 1,2 Diese systemische Therapie der Psoriasis wurde durch die Einführung von bestimmten monoklonalen Antikörpern und Fusionsproteinen (auch Biologika genannt) revolutioniert und seitdem stetig um besser wirksamere Substanzen erweitert (zuletzt anti-Interleukin-17-und anti-Interleukin-23-Antikörper). Aktuelle Analysen zeigten jedoch, dass 14,6-78,4% der Patient:innen im klinischen Alltag nicht für Zulassungsstudien dieser Arzneimittel in Frage gekommen wären.…”